Solution to treat advanced-stage cancers under way in Russia
TheraMAB, a Russian biotech company, has launched a new phase of clinical trials for its drug candidate, designated TAB08, to treat cancers at advanced stages, reported the website of RVC, Russia’s fund of funds for innovation. RVC has a shareholding in the biotech developer through Bioprocess Capital Ventures, a VC fund co-owned by RVC.